Home › Funds › ADAR1 Capital Management, LLC › MNPR
ADAR1 Capital Management, LLC position in MNPR
MONOPAR THERAPEUTICS INC · Health Care
ADAR1 Capital Management, LLC reported holding 217,595 shares of MNPR (MONOPAR THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$20.1M, representing 1.12% of its reported portfolio and ranking #20 among its reported holdings. ADAR1 Capital Management, LLC has disclosed MNPR holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How ADAR1 Capital Management, LLC's MNPR position evolved
ADAR1 Capital Management, LLC first disclosed a stake in MNPR in Q4 2024 at 130,037 shares (US$2.9M). The position peaked in Q2 2026 at 217,595 shares, worth US$20.1M. Across 7 filings, ADAR1 Capital Management, LLC increased the stake 3 time(s), trimmed it 2 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 217,595 shares valued at US$20.1M — a reduction of -46,683 shares quarter over quarter.. Notable position changes include a 29% increase in Q3 2025 (shares fell 20% over the following quarter), a 80% increase in Q4 2025 (shares fell 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2024 | 130.04K | $2.86M | New |
| Q1 2025 | 100.77K | $3.67M | Reduce |
| Q2 2025 | 100.97K | $3.61M | Hold |
| Q3 2025 | 130.00K | $10.62M | Add |
| Q4 2025 | 233.91K | $15.27M | Add |
| Q1 2026 | 264.28K | $14.48M | Add |
| Q2 2026 | 217.59K | $20.15M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MNPR and 13F data
MNPR (MONOPAR THERAPEUTICS INC) is a Health Care company. 84 other funds we track also report a position in MNPR — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$61.8M), DEERFIELD MANAGEMENT COMPANY, L.P. (US$30.0M), Saturn V Capital Management LP (US$28.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MNPR
- RA CAPITAL MANAGEMENT, L.P. 667.21K sh · $61.78M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 323.75K sh · $29.98M · Q2 2026
- Saturn V Capital Management LP 311.98K sh · $28.89M · Q2 2026
- Siren, L.L.C. 270.12K sh · $25.01M · Q2 2026
- TCG Crossover Management, LLC 203.33K sh · $18.83M · Q2 2026
- Vivo Capital, LLC 90.50K sh · $8.38M · Q2 2026
- Ikarian Capital, LLC 47.86K sh · $4.43M · Q2 2026
- STEMPOINT CAPITAL LP 30.12K sh · $2.79M · Q2 2026
- Ishara Investments LP 12.30K sh · $1.14M · Q2 2026
- Martin Investment Management, LLC 2.33K sh · $215.46K · Q2 2026
More on ADAR1 Capital Management, LLC
FAQ
How long has ADAR1 Capital Management, LLC held MNPR?
ADAR1 Capital Management, LLC has disclosed MNPR holdings in 7 of the last 7 reported quarters, going back to Q4 2024.
What is ADAR1 Capital Management, LLC's current position in MNPR?
As of Q2 2026, ADAR1 Capital Management, LLC holds 217.59K shares of MNPR (MONOPAR THERAPEUTICS INC), valued at $20.15M, representing 1.12% of its reported portfolio and ranking #20.
Has ADAR1 Capital Management, LLC been buying or selling MNPR?
In the latest 13F filing (Q2 2026), ADAR1 Capital Management, LLC reduced its position in MNPR. The position peaked in Q2 2026 at 217.59K shares.
Which other funds hold MNPR?
Other major institutional holders of MNPR include RA CAPITAL MANAGEMENT, L.P., DEERFIELD MANAGEMENT COMPANY, L.P., Saturn V Capital Management LP, among 84 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.